Insmed, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a $223.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ritu Baral’s rating is based on several positive developments for Insmed. The company’s recent financial performance has been strong, with Brinsupri’s third-quarter revenue significantly surpassing expectations. This success is attributed to a robust early launch in the non-cystic fibrosis bronchiectasis market, with a notable number of patients and prescribers engaged by the end of September.
Additionally, Insmed’s pipeline shows promise with upcoming trial data and new trials set to begin in the near future. The increase in the price target reflects the enhanced value from Brensocatib in chronic rhinosinusitis without nasal polyps. Furthermore, the company’s global revenue guidance for Arikayce has been raised, indicating continued growth and potential for further success. These factors collectively support the Buy rating given by Ritu Baral.